These include combining immune checkpoint blockade (ICB) with chemotherapy, anti–TGF-β agents, CSF1R inhibitors that target tumor-associated macrophages (TAMs), or intravesical immunomodulatory agents designed to remodel the tumor immune microenvironment and enhance antitumor immunity (51). Here, CSF1R is linked to neoplasm.